E-DRUG: Independent Drug and Healthcare Newsletter for March 2018
-------------------------------------------------------------------------------------
Independent Drug & Healthcare Newsletter from the non-profit journal Prescrire International
Newsletter, March 2018
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW : Ceftazidime + avibactam (Zavicefta°). An option in the case of cephalosporin resistance
A ceftazidime + avibactam combination (Zavicefta°, Pfizer) has been approved in the European Union for the treatment of various "complicated" infections. In one clinical trial, the combination was as effective as a carbapenem and had an acceptable adverse effect profile.
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD : In the March issue of Prescrire International: the annual Prescrire Awards for drugs, packaging and information
The three annual Prescrire Awards are granted in total independence by the Prescrire Editorial Staff, based on reviews published over the past year in our French edition.
Read more
--------------------------------------------------------------------------------
Hodgkin disease: two drugs that are not beneficial to patients
In the absence of any proven increase in life expectancy, there is no justification for exposing patients with Hodgkin disease to the many, sometimes severe, adverse effects of nivolumab (Opdivo°) and brentuximab vedotin (Adcetris°).
Read more
--------------------------------------------------------------------------------
Hospitalised children: errors detected by parents and family members
During a child's hospitalisation, family members often detect adverse events and errors which are not noticed or reported by caregivers.
Read more
--------------------------------------------------------------------------------
Early syphilis: screen and treat to prevent transmission
Syphilis is sometimes hard to identify, and so it is important to screen and treat the sexual partners of infected persons to prevent transmission.
Read more
--------------------------------------------------------------------------------
EMA's advice to drug companies: conflicting roles
The European Medicines Agency (EMA) offers "scientific advice" to drug companies to help them compile their marketing authorisation applications, giving rise to suspicions that the agency may be placing pharmaceutical companies' interests over and above patients' health.
Read more
--------------------------------------------------------------------------------
Prescrire's ratings system: new drugs and indications, at a glance
ABOUT PRESCRIRE Behind the annual Prescrire Awards, Prescrire's editors work year-round to assess whether or not new drugs and indications represent a therapeutic advance for patients. Ranging from "Bravo" to "Not Acceptable", Prescrire's ratings sum up the result of a unique, collective editorial process.
Read more
Share this with a friend or colleague: Forward this email
Get this from a friend? Sign up here
Prescrire International <international@prescrire.org>